New Two-Pronged attack tested for Tough-to-Treat prostate cancer
Disease control
Not yet recruiting
This early-stage trial is testing the safety of a new two-drug combination for men with advanced prostate cancer that has spread and is no longer responding to standard hormone treatments. The treatment pairs a radioactive drug that targets cancer cells with an immunotherapy drug…
Phase: PHASE1 • Sponsor: Cellbion Co., Ltd. • Aim: Disease control
Last updated Mar 11, 2026 14:54 UTC